DMXL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Encourageously, the results of the differential analysis were consistent with the GSE13159 cohort, in which NME8, DMXL2, SCD, and FBN1 expression was significantly increased and CXXC5 expression was significantly decreased in newly diagnosed (chronic phase) CML patients (The expression of LINC01268 was not detected).